Emmanuelle Bompas - Concepedia

Author

Emmanuelle Bompas

Also Known As

E Bompas, E. Bompas, EMMANUELLE BOMPAS, Emanuelle Bompas, Emmanuelle BOMPAS, Emmanuelle Bompas, Jaroslav Vanasek, Thibaud Valentin, emmanuelle Bompas

340

Publications

12.8K

Citations

H-Index

Concepts

All Affiliations

Institut Gustave Roussy Centre Léon Bérard Centre Oscar Lambret Institut Bergonié Institut Curie

About

Emmanuelle Bompas is an author at Institut Gustave Roussy specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	41	77	7.1K
2	Health Sciences	16	20	1.6K
3	Cell Biology	2	2	395
4	Diagnostic Sciences	1	1	15
5	Endocrinology	1	1	11

Emmanuelle Bompas

129

Publications

11.9K

Citations

H-Index

Page 1

	Year	Citations
Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study Nicolas Penel, Binh Bui, Jacques‐Olivier Bay, Journal of Clinical Oncology	2008	683
Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group Jean‐Yves Blay, Axel Le Cesne, Isabelle Ray‐Coquard, Journal of Clinical Oncology	2007	390
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas Maud Toulmonde, Nicolas Penel, Julien Adam, JAMA Oncology	2017	381
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study Philippe A. Cassier, Antoîne Italiano, Carlos Gomez-Roca, The Lancet Oncology MedicineImmunologyPathologySoft TissueImmune Checkpoint Inhibitor	2015	356
Improved survival using specialized multidisciplinary board in sarcoma patients Jean‐Yves Blay, Pauline Soibinet, Nicolas Penel, Annals of Oncology Surgical OncologySpecialized Multidisciplinary BoardMedicineCancer ManagementPrognosis	2017	349
Surgery in reference centers improves survival of sarcoma patients: a nationwide study Jean‐Yves Blay, Charles Honoré, Eberhard Stoeckle, Annals of Oncology	2019	307
Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial Antoîne Italiano, Olivier Mir, Simone Mathoulin‐Pélissier, The Lancet Oncology Surgical OncologyAdvanced Ewing SarcomaMedicineMetronomic TherapyPharmacotherapy	2020	306
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study Florence Duffaud, Olivier Mir, Pascaline Boudou‐Rouquette, The Lancet Oncology OncologyAdult PatientsMetronomic TherapyClinical TrialsMetastatic Osteosarcoma	2018	304
Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial Olivier Mir, Thomas Brodowicz, Antoîne Italiano, The Lancet Oncology OncologyMetronomic TherapyClinical TrialsPharmacotherapyCancer Treatment	2016	276
Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis Philippe A. Cassier, Hans Gelderblom, Silvia Stacchiotti, Cancer	2011	258

Page 1